valrubicin / Generic mfg. - LARVOL DELTA

Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis. (PubMed, Cureus) - "Identical exclusions were applied to both cohorts for anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin, and valrubicin), immune checkpoint inhibitors (nivolumab and pembrolizumab), and lymphoma coded as "in remission." Outcomes were assessed beginning one day after cohort entry (index event).  The primary outcome was TLS (ICD-10-CM E88.3). Median TLS-free survival was not reached in either cohort within available follow-up.  Conclusions In this propensity-matched real-world cohort restricted to cyclophosphamide/ifosfamide exposure and excluding anthracyclines and immune checkpoint inhibitors, Burkitt lymphoma was associated with higher TLS incidence and shorter TLS-free survival compared with MCL. These findings support classifying Burkitt lymphoma as a higher-risk phenotype at treatment initiation and adopting more intensive TLS prevention and monitoring strategies (particularly proactive hydration and closer biochemical..."

Journal • Acute Kidney Injury • Burkitt Lymphoma • Cardiovascular • CNS Disorders • Epilepsy • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Nephrology • Oncology • Renal Cell Carcinoma • Renal Disease

Cross-Species Transcriptomic and Network Analysis of Human and Canine Diffuse Large B-Cell Lymphoma Identifies a Conserved Replication-DNA Damage Module for Drug Repurposing. (PubMed, Vet Comp Oncol) - "Querying the Connectivity Map/LINCS library with the human component of the module highlighted anthracycline-like topoisomerase II poisons (valrubicin, etoposide, amsacrine) and the PARP inhibitor rucaparib among the ~0.2% most negative connectivity scores, while directly targeting TOP2A and/or PARP1. Finally, extracellular-vesicle microRNA (EV-miRNA) profiling in human DLBCL showed that differentially expressed EV-miRNAs, including let-7 family members, miR-21-5p, miR-124-3p and miR-205-5p, converge on the same TOP2A/PARP1-centred core. These cross-species, multi-layer data support topoisomerase II poisons and PARP inhibition as coherent, network-anchored candidate therapies for canine DLBCL, with module scores and EV-miRNAs as candidate biomarkers."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • MIR124-3 • MIR205 • MIR21 • TOP2A

Quality care measures among patients with high-risk non-muscle invasive bladder cancer with papillary carcinoma or carcinoma in situ receiving front-line Bacillus Calmette-Guérin or other intravesical therapies (AUA 2026) - " This retrospective study used SEER-Medicare data (01/01/2007–12/31/2022) to include patients ≥65 years with HR-NMIBC with PAP (T1 or high-grade Ta) or CIS (Tis or CIS diagnosis), and ≥1 instillation of BCG (BCG cohort) or other IVT (IVT cohort; mitomycin, gemcitabine, valrubicin, docetaxel, epirubicin). Important gaps in care remain for patients with HR-NMIBC with PAP or CIS treated with front-line BCG or other IVTs across monitoring, treatment, and healthcare services. Routine assessment of HR-NMIBC-related QoC measures may help close these gaps and improve outcomes for patients receiving front-line bladder-sparing therapy."

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States. (PubMed, J Med Econ) - "Patients treated with TAR-200 monotherapy were compared to those treated with pembrolizumab, nadofaragene firadenovec (NF), nogapendekin alfa inbakicept (NAI)+BCG (with/without reinduction), or valrubicin based on published clinical trial data. Model inputs were based on trial publications, possibly limiting generalizability. TAR-200 demonstrated the highest proportion of patients achieving and sustaining CR for ≥12 months, yielding substantial cost savings per responder compared to other FDA-approved treatments for BCG-unresponsive HR-NMIBC with CIS."

HEOR • Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Patient-derived model systems of endometrial cancers for disease modeling and drug sensitivity testing (AACR 2024) - "The drug screening results clearly highlighted several standout drugs, including CUDC-907 (a dual PI3K/HDAC inhibitor), two histone deacetylase (HDAC) inhibitors including romidepsin and panobinostat, four topoisomerase II (TOP II) inhibitors including mitoxantrone, daunorubicin, doxorubicin, and epirubicin, two proteasome inhibitors including carfilzomib and bortezomib, 2 DNA-directed RNA synthesis inhibitor dactinomycin and plicamycin, omacetaxine mepesuccinate (protein synthesis inhibitor), and valrubicin (DNA synthesis inhibitor). Our unique PDXs and PDCs are excellent models for representing various characteristics of EC and testing novel therapeutics. This current study presents a promising direction for developing personalized therapy options for EC patients and provides a platform for further investigation of drug mechanisms and tumor development. Future studies will also involve etiology, such as chronic psychological stress, DNAm age and intratumoral microbiome."

Clinical • Endometrial Cancer • Gynecologic Cancers • Oncology • Solid Tumor

PELP1 inhibition enhances the therapeutic efficacy of topoisomerase inhibitors in triple-negative breast cancer (AACR 2024) - "Of the five drugs, the three drugs Gemcitabine, Valrubicin, and Mitoxantrone, induced DNA damage by inhibiting topoisomerase, a protein that cleaves and reconnects DNA during replication. Together, these results suggest a novel targeted therapy for the treatment of TNBC, involving the combination of topoisomerase inhibitors and the PELP1 inhibitor SMIP34."

Clinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ANXA5 • PELP1 • TOP2A

Front-line (1L) treatment and recurrence patterns among patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with papillary carcinoma (PAP) or carcinoma in situ (CIS) following bacillus Calmette-Guérin (BCG) or other intravesical therapies (IVT). (ASCO-GU 2026) - " This retrospective cohort study using SEER-Medicare data (1/1/2007-12/31/2022) included treatment-naïve patients ≥65 years old with HR-NMIBC with PAP (T1 disease or high-grade Ta) or CIS (Tis staging or diagnosis code), who received ≥1 instillation of BCG (BCG cohort) or other IVT (IVT cohort; mitomycin, gemcitabine, valrubicin, docetaxel, epirubicin) as 1L treatment...Recurrence was defined as reinitiation of the same therapy after a gap (BCG: ≥180-day gap; other IVT: ≥90-day gap), transurethral resection of bladder tumor (TURBT), biopsy, or initiation of a new treatment (i.e., alternative IVT, systemic chemotherapy, radiotherapy, cystectomy, immunotherapy [including pembrolizumab], hormonal therapy, or other antineoplastic therapy)... In this real-world study of Medicare-insured patients with HR-NMIBC with PAP or CIS, over 60% experienced recurrence within 12 months of initiating 1L BCG or IVT. While most BCG-treated patients received adequate induction, just..."

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy. (PubMed, Cell Rep Med) - "Across four murine cancer models, two responsive (T and B lymphomas) and two resistant (orthotopic breast and lung cancers), Val-ILs decorated with antibodies against the nine targets significantly enhance anti-PD-1 efficacy. This combination boosts the presence of CD4+ and CD8+ tumor-infiltrating lymphocytes, reprograms tumor-associated macrophages toward an M1-like phenotype, and improves tumor control and metastasis reduction."

IO biomarker • Journal • Breast Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Oncology • Solid Tumor • CD4 • CD8 • ITGA2 • ITGAM • KDR • KIM1 • LAG3 • MSR1

A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania. (PubMed, Arch Ital Urol Androl) - "Though RC remains the predominant approach for BCG-unresponsive cases, over half of urologists' report using intravesical chemotherapy, reflecting interest in bladder-sparing strategies rather than newly approved FDA agents."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Cost per Responder of TAR-200 vs. Other FDA-Approved Novel and Generic Treatments Among Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ in the United States (ISPOR-EU 2025) - "Patients treated with TAR-200 monotherapy were compared to those treated with pembrolizumab, nadofaragene firadenovec (NF), nogapendekin alfa inbakicept (NAI)+BCG (with and without reinduction), or valrubicin based on published clinical trial data. TAR-200 demonstrated the highest proportion of patients achieving and sustaining CR for ≥12 months, translating to substantial cost savings per responder compared to other FDA-approved treatments for BCG-UR HR-NMIBC with CIS."

Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Host-Guest Complexes of Cucurbituril with the neutral Guest Valrubicin: An Experimental and Computational Study. (PubMed, Drug Dev Ind Pharm) - "IntroductionValrubicin (VAL) is an N-trifluoroacetyl 14-valerate derivative of the anthracycline doxorubicin (DOX)and is known to have anti-tumor activity. The VAL-CB [7, 8] complex exhibited a 220,000-fold solubility increase, enhanced stability, and a sustained release profile.ConclusionThe CB-VAL complex significantly enhanced physicochemical properties of VAL in aqueous solutions, with superiority for CB8. These results highlight the potential of CB7 and CB8 as novel drug delivery systems for hydrophobic drugs, offering a strategy to overcome the limitations of existing solubilization approaches in cancer therapy."

Journal • Oncology

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer. (PubMed, BJU Int) - "Multi-line BST is feasible and can yield durable bladder preservation and oncological control in select patients with HR-NMIBC following BCG failure. Progression-free outcomes remained favourable across successive lines of salvage therapy. These findings support the role of longitudinal BST as an alternative to radical cystectomy in carefully and appropriately selected patients."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Necrotizing Sialometaplasia of Tubarial Glands With Rouvière Lymphadenitis Complicating Postradiotherapy Tumor Follow Up. (PubMed, Laryngoscope) - "Tubarial gland location is shown in D (original scheme from Valstar, Matthijs, et al. Radiotherapy and Oncology, 154, 292-298: with permission)."

Journal • Oncology

Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer. (PubMed, Eur Urol Focus) - "Val/Doce was safe and efficacious in patients with recurrent HR-NMIBC. The capacity to delay progression and avoid RC in a significant proportion of patients highlights its potential as a valuable treatment option in this challenging clinical context and warrants prospective evaluation."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Treatment patterns and clinical outcomes in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (AUA 2025) - "A majority (70%) of these patients received intravesical chemotherapy (specifically 30% gemcitabine, 46% mitomycin, 11% gemcitabine-docetaxel, 12% valrubicin), while 17% underwent radical cystectomy (Figure 1). Despite the recommended standard of care being radical cystectomy, analyses using real-world data from the AQUA Registry demonstrated that most patients initiated intravesical chemotherapy within one year of adequate BCG. Furthermore, the intravesical therapies did not provide durable responses, demonstrating the unmet need for innovative bladder-sparing treatments in this patient population."

Clinical • Clinical data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urology

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors. (PubMed, Biochim Biophys Acta Mol Basis Dis) - "Among those 147 drugs we found doxorubicin, daunorubicin, epirubicin, valrubicin, teniposide, afatinib, carmustine, vincristine, panobinostat, and vorinostat to have increased toxicity to cancer cells expressing the rapid NAT2 allele. Additionally, we report NAT2-mediated acetylation of idarubicin, daunorubicin, doxorubicin, vorinostat, and CUDC-101. These findings have implications for pharmacogenomics and cancer precision medicine using conventional chemotherapeutic drugs, as improving their efficacy and safety may affect >4 million cancer patients worldwide that receive these drugs as standard of care."

Journal • Oncology • NAT2

Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review. (PubMed, Clin Genitourin Cancer) - "After BCG-unresponsive disease, most patients with high-risk NMIBC received BCG rechallenge with or without other therapies, and > 25% experienced disease progression within the first 3 years. Effective bladder-sparing options for BCG-unresponsive NMIBC are needed."

HEOR • Journal • Real-world evidence • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Multidrug micelles and sonopermeation for chemotherapy co-delivery to brain tumors. (PubMed, J Control Release) - "Via high-throughput screening of various chemotherapy combinations in different glioma cell lines, valrubicin and panobinostat were identified as a synergic drug combination and co-loaded in mPEG-b-p(HPMAm-Bz)-based polymeric micelles. In orthotopically inoculated patient-derived HSJD-DIPG-007 diffuse intrinsic pontine gliomas, notoriously known to have an intact BBB and poor drug responsiveness, we provide initial experimental evidence showing that multidrug micelles plus sonopermeation can help to improve treatment efficacy. Our work exemplifies that synergistic drug combinations can be efficiently co-loaded in polymeric micelles, and that advanced nanosonochemotherapy combination regimens hold promise for the treatment of hard-to-treat brain cancers."

Journal • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Glioma • Oncology • Solid Tumor

Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice. (PubMed, Res Rep Urol) - "However, systemic immunotherapy with pembrolizumab or gene therapy with intravesical nadofaragene firadenovec may be administered for patients unfit or unwilling to undergo radical cystectomy with outcomes superior to intravesical docetaxel, gemcitabine or valrubicin. The last years have been exciting regarding new developments in this field after a long period of stagnation. Unfortunately, data available on some alternative therapies are mainly limited mainly to Phase I or II studies with a lack of robust evidence, but a clear trend in future treatments has just been drawn."

Journal • Review • Bladder Cancer • Gene Therapies • Genito-urinary Cancer • Oncology • Solid Tumor

Chemoresistance-Motility Signature of Molecular Evolution to Chemotherapy in Non-Muscle-Invasive Bladder Cancer and Its Clinical Implications. (PubMed, Cancer Lett) - "In addition, we identified five drugs that can be used with gemcitabine in these patients, including doxorubicin, docetaxel, paclitaxel, napabucacin, and valrubicin, and verified their efficacy. The CrM signature can assess NMIBC prognosis and BCG treatment response, suggesting alternative treatments. Furthermore, these results need to be prospectively validated."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urology • CAFs • TGFB1

Evidence is not sufficient to declare the tubal gland conglomerates as salivary. (PubMed, Radiother Oncol) - "The letter to Editor is regarding an article by Pringle et al., 2023 which presents the histological and immunohistochemical characterization of the submucosal seromucous gland conglomerate at the nasopharyngeal end of the auditory tube (AT) and compares the same with the major and minor salivary glands, while trying to substantiate the claims of a previous work by Valstar et al., 2021...They mentioned that AT glands are "taxonomically different from the salivary glands" based on their anatomical location along the respiratory tract, the overlying mucosa lined with respirator yepithelium, and the absence of enzyme salivary amylase. This letter presents data from the already existing literature to emphasise the fact that the evidence given by Pringle et al., 2023 are not sufficient to declare the tubal gland conglomerates as salivary."

Journal

Repurposing Valrubicin as a Potent Inhibitor of Ovarian Cancer Cell Growth. (PubMed, Anticancer Res) - "Valrubicin, through drug repositioning, can be applied as a new therapeutic agent for OC."

Journal • Oncology • Ovarian Cancer • Solid Tumor • CASP3

Identification of novel anti-leishmanials targeting glutathione synthetase of the parasite: a drug repurposing approach. (PubMed, FEBS Lett) - "Here, we evaluated four FDA-approved drugs-valrubicin, ciclesonide, deflazacort, and telithromycin-for their anti-leishmanial activity on Leishmania donovani parasites, especially their ability to target the enzyme glutathione synthetase (LdGS), which enables parasite survival under oxidative stress in host macrophages. Subsequent testing on amastigotes revealed the IC50 values of 1.74 ± 0.05 μm and 3.32 ± 0.21 μm for valrubicin and ciclesonide, respectively. Molecular and cellular level analysis further elucidated the mechanisms underlying the anti-leishmanial activity of valrubicin and ciclesonide."

Journal • Infectious Disease

Integrating network analysis with differential expression to uncover therapeutic and prognostic biomarkers in esophageal squamous cell carcinoma. (PubMed, Front Mol Biosci) - "We also identify the molecules targeting these essential hub genes, among which GSK461364 is a promising inhibitor of PLK1, BMS265246, and Valrubicin inhibitors of CDK1 and TOP2A, respectively. Notably, MMP9 emerged as a significant prognostic marker with high expression correlating with poor survival, underscoring its potential for targeted therapy. These findings enhance our understanding of ESCC pathogenesis and highlight promising avenues for treatment."

Biomarker • Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology • Squamous Cell Carcinoma • CDK1 • MAD2L1 • MMP9 • PLK1 • TOP2A

New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer. (PubMed, Bladder Cancer) - "Considering the plethora of novel intravesical treatments that have completed phase II evaluation, one can reasonably expect that clinicians will soon have at their disposal new agents and treatment options for BCG-unresponsive NMIBC. In the near future, it will be up to the urologist to identify, for each specific patient, the right agent to use, based on safety, results and cost-effectiveness."

Journal • Review • Bladder Cancer • Gene Therapies • Genito-urinary Cancer • Oncology • Solid Tumor • Urology